Chief of Sarcoma Service and Chair of the Department of Surgery
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardia, Italy
Alessandro Gronchi MD received his MD degree from Milan University in 1992, completed his residency training in General Surgery in 1997 and a fellowship in Surgical Oncology in 1998. He holds the National Scientific qualification for full professor of General Surgery. He is chief of Sarcoma Service since 2001 and chair of the department of Surgery since 2022 at the National Cancer Institute (Fondazione IRCCS Istituto Nazionale dei Tumori) – Milan – Italy.
He is involved in all institutional research activities on sarcoma, which include neoadjuvant therapies in extremity and retroperitoneal sarcomas, new targets for specific STS types, genomic characterization of DF and its impact in tumor progression, mechanisms of resistance to therapy in GIST. He is the Principal Investigator of several Italian and International trials on STS, DF and GIST.
He serves as member of the board of directors of the Italian Sarcoma Group, member of the board of directors of the European Society of Surgical Oncology 2020-2024; international representative on the executive council of the SSO 2021-2024; member of the Sarcoma Task Force of the European Society for Medical Oncology. He was chair of the EORTC Soft Tissue and Bone Sarcoma Group (2015-2017), president of the Connective Tissue Oncology Society (2016); president of the Italian Society of Surgical Oncology (2019-2021). He is member of the European Surgical Association, the American Society of Clinical Oncology and honorary member of the Polish Society of Surgical Oncology. He is one of the initiators of a global collaborative effort on retroperitoneal sarcoma (Trans-atlantic Australasian RetroPeritoneal Sarcoma Working Group, TARPSWG), which involves over 200 institutions worldwide. Dr. Gronchi has authored more than 520 scientific publications (Scopus HIndex 101), serves as Associate Editor of Annals of Surgical Oncology, Journal of Surgical Oncology, Critical Reviews in Oncology/Hematology, Therapeutics Advances in Medical Oncology; Updates in Surgery.
Disclosure information not submitted.
Thursday, November 14, 2024
1:45 PM – 3:15 PM PST
Friday, November 15, 2024
8:00 AM – 9:00 AM PST
Friday, November 15, 2024
8:00 AM – 9:00 AM PST
Friday, November 15, 2024
8:00 AM – 9:00 AM PST
Saturday, November 16, 2024
1:00 PM – 2:00 PM PST
Paper 100 - REDEFINING RADIOLOGIC RESPONSE IN EPITHELIOID HEMANGIOENDOTHELIOMA: BEYOND RECIST?
Saturday, November 16, 2024
2:00 PM – 3:00 PM PST
Saturday, November 16, 2024
3:30 PM – 4:30 PM PST